Jpmorgan Chase & CO Amylyx Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 57,511 shares of AMLX stock, worth $285,254. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,511

Previous 409,759 85.96%

Holding current value

$285,254

Previous $1.16 Million 90.63%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.62 - $2.71 $570,641 - $954,592	-352,248 Reduced 85.96%	57,511 $109,000
Q1 2024 May 10, 2024	BUY	$2.71 - $19.57 $915,630 - $6.61 Million	337,871 Added 470.0%	409,759 $1.16 Million
Q4 2023 Feb 12, 2024	SELL	$12.07 - $18.46 $230,259 - $352,161	-19,077 Reduced 20.97%	71,888 $1.06 Million
Q3 2023 Nov 14, 2023	SELL	$18.08 - $23.45 $1.8 Million - $2.33 Million	-99,331 Reduced 52.2%	90,965 $1.67 Million
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $1.86 Million - $2.78 Million	88,596 Added 87.12%	190,296 $4.1 Million
Q1 2023 May 18, 2023	BUY	$27.71 - $40.93 $1.61 Million - $2.38 Million	58,099 Added 133.25%	101,700 $2.98 Million
Q1 2023 May 11, 2023	SELL	$27.71 - $40.93 $169,031 - $249,673	-6,100 Reduced 12.27%	43,601 $1.28 Million
Q4 2022 Feb 13, 2023	BUY	$29.75 - $39.26 $905,500 - $1.19 Million	30,437 Added 158.0%	49,701 $1.84 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $225,213 - $406,041	13,132 Added 214.16%	19,264 $542,000
Q2 2022 Aug 11, 2022	BUY	$6.85 - $19.93 $11,199 - $32,585	1,635 Added 36.36%	6,132 $118,000
Q1 2022 May 11, 2022	BUY	$12.85 - $32.9 $57,786 - $147,951	4,497 New	4,497 $58,000

Others Institutions Holding AMLX

# of Institutions

139

Shares Held

46.5M

Call Options Held

226K

Put Options Held

909K

View Full List

About Amylyx Pharmaceuticals, Inc.

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

More about AMLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Amylyx Pharmaceuticals, Inc. Transaction History